Towards a new therapy
for the treatment of
Malignant Mesothelioma

EN · ES · CAT

A Novel BERberine derivative for Malignant MESothelioma

Asbestos exposure is the main risk factor for malignant mesothelioma. This rare and lethal cancer affects the mesothelium: the protective thin layer of tissue that covers many of the internal organs of the body. The tumour has a long latency period taking 20 to 50 years to appear. Because of its aggressiveness and highly resilience, researchers are on the hunt for newer and better treatment strategies. This is indeed the main goal of BERMES: developing a novel molecule with a disruptive mechanism of action that has shown activity in this hard-to-treat tumour.

 

WATCH VIDEO ►

 

Follow the most recent news of the project in Twitter @BermesProject

Imagen Elemento web

Malignant mesothelioma is a rare, aggressive and highly resilient malignancy that affects the arising in the thin layer of tissue known as mesothelium, which covers many of the important internal organs like the lungs, the peritoneal cavity, the heart and the testis.

Read more...

Imagen Elemento web

NAX035 is a novel and selective anticancer agent with a superior profile for oncology conditions. It is a derivative of natural alkaloid Berberine which shows superior activity and pharmacology and safety profile. It shows robust preclinical proof of concept in several in vitro and animal models.

Read more...

05/03/2024 - Meet us at Bioequity Europe 2024
Aromics and Bermes Project will be present at Bioequity Europe 2024 conference....

Read more...

04/02/2024 - IDEA2 2024 meeting
Dr. Carmen Plasencia, CEO f AROMICS presents the advances of our projects at...

Read more...

CDTI Innovación
Plan de Recuperación, Transformación y Resiliencia
NextGenerationEU
Unión Europea